Indevus Adds Senior VP-Clinical Development From Praecis
This article was originally published in The Pink Sheet Daily
James Shipley, MD, will support medical affairs and post-marketing safety surveillance for the overactive bladder agent Sanctura. He will also evaluate development strategies for pipeline products.
You may also be interested in...
A daily dose of Sanctura – two 20 mg tablets – will carry an average wholesale price of $2.98. Retail pharmacies will begin receiving initial shipments of the incontinence agent over the next week, Indevus said.
Providers are signing up to prescribe the prostate cancer drug through Praecis’ closed distribution system but waiting for a clear coverage determination before delivering the drug to patients, the company says. Praecis is proposing coverage for listed indications and clinical trials.
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.